Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Inoviq Ltd ( (AU:IIQ) ) has shared an announcement.
INOVIQ Limited has announced that its new cancer treatment, CAR-NK-EVs, has demonstrated the ability to kill 88% of breast and lung cancer cells in laboratory tests. This advancement highlights the potential of INOVIQ’s exosome platform to offer a more efficient, safer, and potentially more effective alternative to traditional CAR-T therapies. The announcement underscores the company’s commitment to advancing cancer treatment options and may enhance its positioning within the biotechnology sector.
More about Inoviq Ltd
INOVIQ Limited operates in the biotechnology industry, focusing on the development of innovative cancer treatments. The company specializes in creating CAR-NK-EVs, a type of exosome platform derived from an immortalized NK92 cell line, aimed at providing allogeneic or ‘off-the-shelf’ therapies for cancer treatment.
Average Trading Volume: 222,450
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$42.98M
Learn more about IIQ stock on TipRanks’ Stock Analysis page.